NEW YORK (GenomeWeb) – Biocept said today that it has made a preferred provider agreement with Harle Group subsidiary HarlePhil Ventures to market and distribute the company's Target Selector liquid biopsy assays in the Republic of the Philippines.
Under the terms of the agreement, Biocept will still perform all diagnostic testing in its San Diego-based CLIA lab. HarlePhil will be responsible for sales, marketing, and distribution, and for managing reimbursements in the Philippines. Additional terms of the transaction were not disclosed.
The deal is Biocept's first in Southeast Asia. It now has three international distribution partnerships, including two other agreements inked this year in Israel and Mexico.
The firm also anticipates expanding into additional international markets, President and CEO Michael Nall said in a statement.